Altimmune, Inc. (NASDAQ:ALT) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp increased its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 77.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,752 shares of the company’s stock after buying an additional 7,746 shares during the quarter. Stifel Financial Corp’s holdings in Altimmune were worth $109,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in shares of Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after buying an additional 335,444 shares during the last quarter. Bellevue Group AG raised its stake in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Altimmune during the 2nd quarter worth approximately $689,000. Exchange Traded Concepts LLC lifted its position in Altimmune by 74.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock worth $1,331,000 after acquiring an additional 92,498 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Altimmune by 28.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company’s stock valued at $1,621,000 after purchasing an additional 54,154 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Stock Down 4.6 %

Shares of ALT opened at $7.32 on Tuesday. Altimmune, Inc. has a 52-week low of $5.28 and a 52-week high of $14.84. The company has a 50-day simple moving average of $8.02 and a 200-day simple moving average of $7.14. The company has a market capitalization of $520.64 million, a PE ratio of -4.72 and a beta of 0.15.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period last year, the business posted ($0.39) earnings per share. On average, research analysts anticipate that Altimmune, Inc. will post -1.36 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ALT shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. UBS Group initiated coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.